195 related articles for article (PubMed ID: 22685259)
1. Non-invasive urine based tests for the detection of bladder cancer.
Wadhwa N; Jatawa SK; Tiwari A
J Clin Pathol; 2012 Nov; 65(11):970-5. PubMed ID: 22685259
[TBL] [Abstract][Full Text] [Related]
2. Republished: non-invasive urine based tests for the detection of bladder cancer.
Wadhwa N; Jatawa SK; Tiwari A
Postgrad Med J; 2013 Jun; 89(1052):352-7. PubMed ID: 23686844
[TBL] [Abstract][Full Text] [Related]
3. [Bladder cancer biomarkers].
Dobrowolska-Glazar B; Glazar W; Dobrowolski Z; Lipczyński W
Przegl Lek; 2010; 67(7):479-83. PubMed ID: 21387760
[TBL] [Abstract][Full Text] [Related]
4. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
5. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
[TBL] [Abstract][Full Text] [Related]
6. Urine based markers of urological malignancy.
Konety BR; Getzenberg RH
J Urol; 2001 Feb; 165(2):600-11. PubMed ID: 11176445
[TBL] [Abstract][Full Text] [Related]
7. Urinary biomarkers of bladder cancer: an update and future perspectives.
Rosser CJ; Urquidi V; Goodison S
Biomark Med; 2013 Oct; 7(5):779-90. PubMed ID: 24044570
[TBL] [Abstract][Full Text] [Related]
8. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
9. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the sensitivity and specificity of urine cytology, urinary nuclear matrix protein-22 and multitarget fluorescence in situ hybridization assay in the detection of bladder cancer.
Kehinde EO; Al-Mulla F; Kapila K; Anim JT
Scand J Urol Nephrol; 2011 Mar; 45(2):113-21. PubMed ID: 21091091
[TBL] [Abstract][Full Text] [Related]
12. Non-invasive diagnostic tests for bladder cancer: a review of the literature.
Bassi P; De Marco V; De Lisa A; Mancini M; Pinto F; Bertoloni R; Longo F
Urol Int; 2005; 75(3):193-200. PubMed ID: 16215303
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
14. Increased accuracy of a novel mRNA-based urine test for bladder cancer surveillance.
Pichler R; Fritz J; Tulchiner G; Klinglmair G; Soleiman A; Horninger W; Klocker H; Heidegger I
BJU Int; 2018 Jan; 121(1):29-37. PubMed ID: 28941000
[TBL] [Abstract][Full Text] [Related]
15. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
16. Urine markers for detection and surveillance of bladder cancer.
Xylinas E; Kluth LA; Rieken M; Karakiewicz PI; Lotan Y; Shariat SF
Urol Oncol; 2014 Apr; 32(3):222-9. PubMed ID: 24054865
[TBL] [Abstract][Full Text] [Related]
17. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
18. Urinary markers in the detection of bladder cancer: what's new?
Nielsen ME; Schaeffer EM; Veltri RW; Schoenberg MP; Getzenberg RH
Curr Opin Urol; 2006 Sep; 16(5):350-5. PubMed ID: 16905981
[TBL] [Abstract][Full Text] [Related]
19. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
20. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]